Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Core Insights - Candel Therapeutics announced promising interim data from its phase 1b clinical trial of CAN-3110 in recurrent glioblastoma, along with a publication in a high-impact journal [1][2] Clinical Trial Findings - The publication details findings from 97 tumor biopsies from two patients, revealing a discordance between immune biomarkers and imaging results, indicating that conventional imaging may misinterpret immune infiltration as disease progression [3][5] - CAN-3110 induced significant changes in the tumor microenvironment, with one patient achieving a complete pathological response [3][4] - The study identified T cell clonotypes targeting CAN-3110 epitopes, supporting the dual mechanism of action of the therapy [4][5] Survival Data - Updated median overall survival (mOS) was reported as 11.8 months for arm A and 12.0 months for arm B, with some patients surviving significantly longer [5][6] - In arm C, 9 patients received multiple administrations of CAN-3110, with a median follow-up of 8.9 months; 4 out of 9 patients were alive at the time of data cutoff [6] Future Directions - The company plans to design a small phase 2 clinical trial for CAN-3110 in recurrent glioblastoma, collaborating with the glioblastoma community and regulators [8] - CAN-3110 has received FDA Fast Track and Orphan Drug Designations, indicating its potential as a treatment for recurrent high-grade glioma [8][11] Company Overview - Candel Therapeutics focuses on developing multimodal biological immunotherapies, with CAN-3110 being a first-in-class oncolytic viral immunotherapy candidate [9][10] - The company has established platforms based on genetically modified adenovirus and herpes simplex virus, with ongoing clinical trials for other product candidates [10][11]